Opinion: STAT+: A moment of reckoning for preventive cardiology and the precision medicine revolution — SkimNews
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Novartis released top-line results from Lp(a) HORIZON, its highly anticipated Phase 3 trial of pelacarsen targeting lipoprotein(a), a genetically determined cholesterol particle strongly associated with heart attack and stroke risk
- Pelacarsen successfully lowered lipoprotein(a) levels in the study but did not move the needle on reducing cardiovascular events
- ZEUS, a Phase 3 trial of Novo Nordisk's ziltivekimab — a monoclonal antibody targeting IL-6 as an anti-inflammatory agent — also impacted its biological target without making a difference in clinical outcomes
- The back-to-back results arrive weeks apart, framing what the piece calls "a moment of reckoning" for preventive cardiology and the precision medicine revolution
- Pelacarsen had been viewed as a potential first approved therapeutic specifically targeting lipoprotein(a), making the clinical-outcome miss especially consequential for that drug class
Why it matters: Pelacarsen and ziltivekimab were each designed as first-in-class therapies for distinct cardiovascular pathways — lipoprotein(a) and IL-6 inflammation — and both validated their molecular hypotheses yet delivered no reduction in heart attacks or strokes, leaving preventive cardiology to reckon with a widening gap between biomarker success and patient outcomes.
Ask SkimNews
